alx148
mAbexperimental
Clinical trial activity
14 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started Feb 3, 2017 (NCT03013218)
Timeline
Indications
Studied for
- Biomarkers · Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 2
- Composite Lymphoma · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 2/Phase 3
- Genes, erbB-2 · Phase 1
- Head and Neck Neoplasms · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Oropharyngeal Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2/Phase 3
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
Leukocyte surface antigen CD47 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297880 ↗
Also known as
- alx148
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07007559 | Phase 1/Phase 2 (Phase 2) | Apr 28, 2025 | ALX Oncology |
| NCT05787639 | Phase 2 | Dec 20, 2023 | University of California, San Diego |
| NCT05868226 | Phase 1 | Dec 22, 2022 | QuantumLeap Healthcare Collaborative, University of Texas at Houston |
| NCT05524545 | Phase 1 | Oct 31, 2022 | ALX Oncology |
| NCT05467670 | Phase 2 | Aug 31, 2022 | ALX Oncology, Merck, University of Pittsburgh |
| NCT05167409 | Phase 2 | Jul 14, 2022 | ALX Oncology, Criterium, Inc., Eli Lilly, Merck, University of Colorado, Denver |
| NCT05025800 | Phase 1/Phase 2 (Phase 2) | Oct 13, 2021 | University of Texas at Houston |
| NCT05027139 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2021 | ALX Oncology, Zymeworks Inc. |
| NCT05002127 | Phase 2/Phase 3 (Phase 3) | Aug 31, 2021 | ALX Oncology, Eli Lilly |
| NCT04675333 | Phase 2 | May 10, 2021 | ALX Oncology, Merck |
| NCT04755244 | Phase 1/Phase 2 (Phase 2) | May 5, 2021 | ALX Oncology |
| NCT04675294 | Phase 2 | Feb 28, 2021 | ALX Oncology, Merck |
| NCT04417517 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2020 | ALX Oncology |
| NCT03013218 | Phase 1 | Feb 3, 2017 | ALX Oncology |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ALX Oncology | For profit | 11 | 8 | 3 | 2017 |
| Merck | For profit | 4 | 0 | 1 | 2021 |
| Eli Lilly | For profit | 2 | 0 | 2 | 2021 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 2 | 2021 |
| Criterium, Inc. | For profit | 1 | 0 | 1 | 2022 |
| QuantumLeap Healthcare Collaborative | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Zymeworks Inc. | For profit | 1 | 1 | 1 | 2021 |
10 organizations
Page 1 / 1